🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSELECT trial: 20% MACE reduction — 6 month update Page 3

SELECT trial: 20% MACE reduction — 6 month update

Admin Tue, Sep 24, 2024 at 8:21 AM 11 replies 1,765 viewsPage 3 of 3
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Sep 30, 2024 at 1:43 PM#11
Dr.NephBHM_UK said:
Relative and absolute effects need reading together.
Dr.NephBHM_UK said:
...cardiovascular risk is just another fad...

I understand the skepticism — we've all seen "miracle" weight loss solutions come and go. But consider what makes GLP-1 agonists different:

  • Phase 3 RCTs with thousands of participants (not 20-person pilot studies)
  • Published in NEJM, JAMA, Lancet (not press releases)
  • Replicated across multiple independent research groups
  • Proven cardiovascular and renal benefits beyond weight loss
  • Biological mechanism fully characterized at the receptor level

This isn't a fad — it's a new drug class supported by the highest level of clinical evidence. The comparison to past fads is understandable but inappropriate.

7 5mike_nyc, VendorMark, COA_Karl and 4 others
Reply Quote Save Share Report
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Sep 30, 2024 at 3:55 PM#12
mike_mod said:
Agreed, and subgroup analyses deserve particular suspicion.

Thank you — that is the clearest version of this I have read, and I have read a lot of them. Printing the relevant bit and taking it with me.

8 6Dr.EndoEP, GraceAZ_72, carl_compliance and 5 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Sep 30, 2024 at 6:07 PM#13
Dr.NephBHM_UK said:
Relative and absolute effects need reading together.

Pushing back on Dr.NephBHM_UK here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

9 7LibrarianMeg, bri_stats, pete_manc_UK and 6 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
bri_stats
Member
789
3,456
May 2024
Seattle, WA
Sep 30, 2024 at 8:19 PM#14
Admin said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my key markers:

Weight: consistent downtrend, -2.2 lbs/week average
Fasting glucose (finger stick): stable at 87 mg/dL
Blood pressure (home): 117/73 average
Resting heart rate: 67 bpm (down from 83)
Waist circumference: down 17 inches total

The resting heart rate improvement correlates with cardiovascular fitness gains. Everything is moving in the right direction.

Last edited: Oct 1, 2024 at 12:19 AM
10 8JessicaM_2024, TomFromTexas, mike.trainer_LA and 7 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Sep 30, 2024 at 10:31 PM#15

Moderator note: a post naming a supplier has been edited. Discuss suppliers in the review sections, not here. Report rather than reply if it drifts again.

11 9PurityPaulOR, MaxMetOK, MounjBrad and 8 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register